About ibritumomab
Radiolabeled monoclonal antibody
Used for
- Treatment of certain types of non-Hodgkin lymphoma, including follicular lymphoma.
Usual adult dose
Given intravenously as a treatment course, with doses based on body weight and blood counts; administered with rituximab and radioactive imaging or therapy doses.
Common side effects
- Low blood-cell counts
- Infections
- Nausea
- Fatigue
Important warnings
- Can cause severe, prolonged reductions in blood-cell counts.
- May increase the risk of serious infections, bleeding, or secondary cancers.
- Treatment requires specialist monitoring and radiation-safety precautions.
- Not suitable during pregnancy.
Pregnancy
Can harm an unborn baby. Pregnancy should be avoided during treatment and for 12 months afterward.
Breastfeeding
Breastfeeding is not recommended during treatment or for 6 months afterward.
Interactions
- Other treatments that suppress bone marrow can increase blood-count problems.
- Live vaccines may be unsafe during treatment and while immune function is reduced.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.